These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 33686365)

  • 41. Detection of SARS-CoV-2-Specific IgA in the Human Milk of COVID-19 Vaccinated Lactating Health Care Workers.
    Valcarce V; Stafford LS; Neu J; Cacho N; Parker L; Mueller M; Burchfield DJ; Li N; Larkin J
    Breastfeed Med; 2021 Dec; 16(12):1004-1009. PubMed ID: 34427487
    [No Abstract]   [Full Text] [Related]  

  • 42. COVID-19: The Vaccine Race Continues.
    Burgess LH; Castelein C; Rubio A; Cooper MK
    HCA Healthc J Med; 2021; 2(2):81-91. PubMed ID: 37425646
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Review on Repurposed Drugs and Vaccine Trials for Combating SARS CoV-2.
    Khanna N; Pawar SV; Kumar A
    Curr Drug Res Rev; 2021; 13(3):203-221. PubMed ID: 33719950
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Insights into COVID-19 vaccines development: Translation from benchside to bedside.
    Houssein M; Al Hossainy AEA; Al Soussi J; El Batch J; El-Samadi L; El Imam S; Fakih R; Dakdouk H; Khalil M
    Health Sci Rev (Oxf); 2022 Sep; 4():100040. PubMed ID: 35856085
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines.
    Uddin MN; Roni MA
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579270
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2.
    Damodharan K; Arumugam GS; Ganesan S; Doble M; Thennarasu S
    RSC Adv; 2021 Jun; 11(33):20006-20035. PubMed ID: 35479882
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines.
    Morais P; Adachi H; Yu YT
    Front Cell Dev Biol; 2021; 9():789427. PubMed ID: 34805188
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy.
    Diotallevi F; Campanati A; Radi G; Martina E; Rizzetto G; Barbadoro P; D'Errico MM; Offidani A
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):1889-1903. PubMed ID: 34586598
    [TBL] [Abstract][Full Text] [Related]  

  • 49. COVID-19 Vaccine Evolution and Beyond.
    Brice Y; Morgan L; Kirmani M; Kirmani M; Udeh MC
    Neurosci Insights; 2023; 18():26331055231180543. PubMed ID: 37351483
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Review of current vaccine development platform to prevent coronavirus disease.
    Arif K; Malhotra S; Mohammad S; Fatima S; Farooqui S; Saleem M
    Natl J Maxillofac Surg; 2022; 13(3):337-346. PubMed ID: 36683946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The status of COVID-19 vaccines in India: A review.
    Jha DK; Pranay K; Samiksha ; Kumar A; Yashvardhini N
    Vacunas; 2023 Apr; ():. PubMed ID: 37362841
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lipid nanoparticles in the development of mRNA vaccines for COVID-19.
    Wilson B; Geetha KM
    J Drug Deliv Sci Technol; 2022 Aug; 74():103553. PubMed ID: 35783677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Syncope With Sinus Arrest Following a Single Dose of a COVID-19 Vaccine.
    Ghoweba M; Sabayon MD
    Cureus; 2023 Jan; 15(1):e34309. PubMed ID: 36860236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications.
    Prabhakar PK; Khurana N; Vyas M; Sharma V; Batiha GE; Kaur H; Singh J; Kumar D; Sharma N; Kaushik A; Kumar R
    Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839773
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An Update on mRNA-Based Viral Vaccines.
    Jeeva S; Kim KH; Shin CH; Wang BZ; Kang SM
    Vaccines (Basel); 2021 Aug; 9(9):. PubMed ID: 34579202
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic.
    Chakraborty C; Sharma AR; Bhattacharya M; Sharma G; Saha RP; Lee SS
    Immune Netw; 2021 Feb; 21(1):e5. PubMed ID: 33728098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines.
    Harris JE
    Health Policy Technol; 2022 Jun; 11(2):100619. PubMed ID: 35340773
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Psychotropic drugs interaction with the lipid nanoparticle of COVID-19 mRNA therapeutics.
    Sfera A; Hazan S; Anton JJ; Sfera DO; Andronescu CV; Sasannia S; Rahman L; Kozlakidis Z
    Front Pharmacol; 2022; 13():995481. PubMed ID: 36160443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Vaccine World of COVID-19: India's Contribution.
    Chavda VP; Vihol DR; Solanki HK; Apostolopoulos V
    Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36423038
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Potential Vaccine Component for COVID-19: A Comprehensive Review of Global Vaccine Development Efforts.
    Khan I; Ahmed Z; Sarwar A; Jamil A; Anwer F
    Cureus; 2020 Jun; 12(6):e8871. PubMed ID: 32754408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.